<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217786</url>
  </required_header>
  <id_info>
    <org_study_id>0868</org_study_id>
    <nct_id>NCT03217786</nct_id>
  </id_info>
  <brief_title>Early Post Transplant Cardiac Allograft Vasculopathy</brief_title>
  <acronym>ECAV</acronym>
  <official_title>Early Post Transplant Cardiac Allograft Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplantation is an effective life-saving treatment for patients with end-stage heart
      disease. After a transplant, the new heart may develop narrowing in the arteries, causing
      heart failure, heart attacks and abnormal heart rhythms. This condition is known as cardiac
      allograft vasculopathy (CAV). The disease is very common, affecting almost a third of heart
      transplant patients by 5 years after transplant. CAV is a serious problem that causes the new
      heart to fail and is one of the main causes of death after transplant. Early detection of CAV
      is important as treatment options are poor once the disease is established. Currently,
      available techniques to evaluate CAV are limited by poor ability to detect disease early. The
      current tests usually focus on the large heart arteries and do not examine the smaller
      arteries that are also affected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine whether early abnormalities of the heart arteries
      after heart transplantation can predict the development of CAV. We will use a combination of
      sophisticated imaging tools to examine in detail the early changes that occur in the arteries
      of a new heart. Heart transplant patients from the University of Ottawa Heart Institute and
      Toronto General Hospital will undergo a series of tests at 3 and 12 months after transplant.
      Statistical analyses will determine whether results from the above tests at 3 months predict
      the development of early CAV at 12 months after a heart transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CAV on invasive coronary studies</measure>
    <time_frame>3 months and 1-year post-transplant.</time_frame>
    <description>Changes in coronary intima on IVUS and OCT and invasive coronary flow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EMBx</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Microvascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Myocardial blood flow quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Serum biomarker panel</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardiac Allograft Vasculopathy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens will be assessed for potential CAV biomarkers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This prospective longitudinal study will involve 2 Canadian adult heart transplant
        programs: University of Ottawa Heart Institute (UOHI, Ottawa) and University Health
        Network-Toronto General Hospital (UHN-TGH, Toronto).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. De novo heart transplant &lt;3 months.

          2. Age ≥18 years.

          3. Able and willing to provide informed consent.

        Exclusion Criteria:

          1. Contraindications to dipyridamole.

          2. Contraindications to aminophylline.

          3. Contraindications to nitroglycerin.

          4. Contraindications to iodinated contrast.

          5. Acute allograft rejection ≤1 month.

          6. Uncontrolled heart failure or myocardial infarction ≤7 days.

          7. Estimated glomerular filtration rate ≤30 mL/min.

          8. Combined solid organ transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Chih, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Chih, MD, PhD</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>14869</phone_ext>
    <email>schih@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aun Yeong Chong, MD</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>14869</phone_ext>
    <email>achong@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Chih</last_name>
      <phone>613-696-7327</phone>
      <phone_ext>67339</phone_ext>
      <email>schih@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Aun Yeung Chong</last_name>
      <phone>613-696-7339</phone>
      <phone_ext>67339</phone_ext>
      <email>achong@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sharon Chih</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Sharon Chih</investigator_full_name>
    <investigator_title>MD, PhD, FRACP</investigator_title>
  </responsible_party>
  <keyword>Macrovascular Disease</keyword>
  <keyword>Microvascular Coronary Artery Disease</keyword>
  <keyword>Cardiac Transplant Rejection</keyword>
  <keyword>Transplant; Failure, Heart</keyword>
  <keyword>Intravascular ultrasound (IVUS)</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Index of Microcirculatory Resistance</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Coronary Flow Reserve</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Endomyocardial Biopsies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

